Targeting tauopathy with engineered tau-degrading intrabodies

by Gilbert Gallardo, Connie H. Wong, Sara M. Ricardez, Carolyn N. Mann, Kent H. Lin, Cheryl E. G. Leyns, Hong Jiang, David M. Holtzman
Published 2019-10-01

Defining the optimal dose and therapeutic window in SMA with respiratory distress type I model mice, FVB/NJ-Ighmpb2 nmd-2J

by Monir Shababi, Caley E. Smith, Sara M. Ricardez Hernandez, Jose Marquez, Zayd Al Rawi, Eric Villalón, K. David Farris, Mona O. Garro-Kacher, Christian L. Lorson
Published 2021-12-01